Penicillamine-induced	penicillamine-induced	O	O	O	O
rapidly	rapidly	O	O	O	O
progressive	progressive	O	O	O	O
glomerulonephritis	glomerulonephritis	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
patient	patient	O	O	O	O
with	with	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
67-year-old	67-year-old	O	O	O	O
woman	woman	O	O	O	O
with	with	O	O	O	O
rheumatoid	rheumatoid	O	DISEASE	OTHERS	I
arthritis	arthritis	O	DISEASE	OTHERS	I
presented	presented	O	O	O	O
rapidly	rapidly	O	O	O	O
progressive	progressive	O	O	O	O
glomerulonephritis	glomerulonephritis	O	DISEASE	OTHERS	I
(	(	O	O	O	O
RPGN	rpgn	O	O	OTHERS	I
)	)	O	O	O	O
after	after	O	O	O	O
5	5	O	O	O	O
months	months	O	O	O	O
of	of	O	O	O	O
D-penicillamine	d-penicillamine	O	O	O	O
(	(	O	O	O	O
250	250	O	O	O	O
mg/day	mg/day	O	O	O	O
)	)	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Light	light	O	O	O	O
microscopy	microscopy	O	O	O	O
study	study	O	O	O	O
showed	showed	O	O	O	O
severe	severe	O	O	O	O
glomerulonephritis	glomerulonephritis	O	DISEASE	OTHERS	I
with	with	O	O	O	O
crescent	crescent	O	O	O	O
formation	formation	O	O	O	O
in	in	O	O	O	O
60	60	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
glomeruli	glomeruli	O	O	O	O
and	and	O	O	O	O
infiltration	infiltration	O	O	O	O
of	of	O	O	O	O
inflammatory	inflammatory	O	O	O	O
cells	cells	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
wall	wall	O	O	O	O
of	of	O	O	O	O
an	an	O	O	O	O
arteriole	arteriole	O	O	O	O
.	.	O	O	O	O

Immunofluorescence	immunofluorescence	O	O	O	O
revealed	revealed	O	O	O	O
scanty	scanty	O	O	O	O
granular	granular	O	O	O	O
IgG	igg	O	O	O	O
,	,	O	O	O	O
IgA	iga	O	O	O	O
and	and	O	O	O	O
C3	c3	O	O	O	O
deposits	deposits	O	O	O	O
along	along	O	O	O	O
the	the	O	O	O	O
capillary	capillary	O	O	O	O
walls	walls	O	O	O	O
and	and	O	O	O	O
mesangium	mesangium	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
was	was	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
steroid	steroid	CHEMICALS	O	OTHERS	I
pulse	pulse	O	O	O	O
,	,	O	O	O	O
plasmapheresis	plasmapheresis	O	O	O	O
,	,	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
antiplatelet	antiplatelet	O	O	OTHERS	I
agents	agents	O	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
complete	complete	O	O	O	O
recovery	recovery	O	O	O	O
of	of	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
was	was	O	O	O	O
achieved	achieved	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
few	few	O	O	O	O
weeks	weeks	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
new	new	O	O	O	O
case	case	O	O	O	O
of	of	O	O	O	O
RPGN	rpgn	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
course	course	O	O	O	O
of	of	O	O	O	O
D-penicillamine	d-penicillamine	O	O	O	O
treatment	treatment	O	O	O	O
emphasizes	emphasizes	O	O	O	O
the	the	O	O	O	O
need	need	O	O	O	O
for	for	O	O	O	O
frequent	frequent	O	O	O	O
monitoring	monitoring	O	O	O	O
of	of	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
and	and	O	O	O	O
evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
urinary	urinary	O	O	O	O
sediment	sediment	O	O	O	O
and	and	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
in	in	O	O	O	O
these	these	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
prompt	prompt	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
D-penicillamine	d-penicillamine	O	O	O	O
and	and	O	O	O	O
vigorous	vigorous	O	O	O	O
treatment	treatment	O	O	O	O
measures	measures	O	O	O	O
could	could	O	O	O	O
allow	allow	O	O	O	O
for	for	O	O	O	O
a	a	O	O	O	O
good	good	O	O	O	O
prognosis	prognosis	O	O	O	O
as	as	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
case	case	O	O	O	O
.	.	O	O	O	O

